Literature DB >> 33210316

Review article: exposure to microbes and risk of coeliac disease.

Ketil Størdal1,2, Christian Kahrs3, German Tapia2, Daniel Agardh4, Kalle Kurppa5,6, Lars C Stene2.   

Abstract

BACKGROUND: Coeliac disease is an immune-mediated intestinal disease characterised by lifelong intolerance to dietary gluten in genetically predisposed individuals. Microbial factors including infections or bacterial microbiota have long been suspected to be involved in the aetiology, but the scientific literature on the topic is scattered and heterogeneous. AIMS: To review human observational studies on microbes and coeliac disease
METHODS: We identified 135 publications judged relevant. Most studies were cross-sectional, and prone to reverse causation and other biases. Only a few were prospective. Cohort studies and longitudinal studies that have sampled biological specimens before disease onset are emphasised in the review.
RESULTS: Infections during early childhood were associated with an increased risk of subsequent coeliac disease in nine studies , whereas maternal infections during pregnancy did not show a clear association. For the most frequently studied microbial factors, some evidence for an association was found, including Helicobacter pylori (four out of 16 studies), adenovirus (two out of nine studies) and enterovirus (two out of six studies). Rotavirus infections have been associated with disease development, and rotavirus vaccination may reduce the risk. Among the many studies of gut microbiota, most were cross-sectional and, therefore, potentially influenced by reverse causation. Only two smaller prospective case-control studies with sampling before disease onset were identified; they reported inconsistent findings regarding the faecal microbiome.
CONCLUSIONS: Several microbes are potentially linked to coeliac disease. As microbial factors are amenable to interventions, larger prospective studies are still warranted.
© 2020 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33210316     DOI: 10.1111/apt.16161

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

Review 1.  Review article: Becoming and being coeliac-special considerations for childhood, adolescence and beyond.

Authors:  Denis Chang; Delia O'Shea; Amelie Therrien; Jocelyn A Silvester
Journal:  Aliment Pharmacol Ther       Date:  2022-07       Impact factor: 9.524

Review 2.  Exposomic determinants of immune-mediated diseases: Special focus on type 1 diabetes, celiac disease, asthma, and allergies: The HEDIMED project approach.

Authors:  Jutta E Laiho; Olli H Laitinen; Johannes Malkamäki; Leena Puustinen; Aki Sinkkonen; Juha Pärkkä; Heikki Hyöty
Journal:  Environ Epidemiol       Date:  2022-06-08

3.  Enterovirus Infections Are Associated With the Development of Celiac Disease in a Birth Cohort Study.

Authors:  Maarit Oikarinen; Leena Puustinen; Jussi Lehtonen; Leena Hakola; Satu Simell; Jorma Toppari; Jorma Ilonen; Riitta Veijola; Suvi M Virtanen; Mikael Knip; Heikki Hyöty
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

4.  Dissecting the contribution of single nucleotide polymorphisms in CCR9 and CCL25 genomic regions to the celiac disease phenotype.

Authors:  Laura Airaksinen; Juliana Xm Cerqueira; Heini Huhtala; Päivi Saavalainen; Dawit A Yohannes; Markku Mäki; Kalle Kurppa; Elina Kilpeläinen; Anastasia Shcherban; Aarno Palotie; Katri Kaukinen; Katri Lindfors
Journal:  J Transl Autoimmun       Date:  2021-10-14

5.  Rotavirus vaccination and the risk of type 1 diabetes and celiac disease: A systematic review and meta-analysis.

Authors:  Xue Zhang; Xiang-Fei Xu; Jie Jin
Journal:  Front Pediatr       Date:  2022-08-26       Impact factor: 3.569

6.  Transglutaminase 2 affinity and enzyme-substrate intermediate stability as determining factors for T-cell responses to gluten peptides in celiac disease.

Authors:  Sunniva F Amundsen; Jorunn Stamnaes; Marie Fleur du Pré; Ludvig M Sollid
Journal:  Eur J Immunol       Date:  2022-07-13       Impact factor: 6.688

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.